DNA Damage Response Alterations Stratify Response to ICI-Based Therapy in Advanced NSCLC with High PD-L1 Expression
Background: Although high PD-L1 expression correlates with improved outcomes to immune checkpoint inhibitor (ICI), it remains an imperfect predictive biomarker. DNA damage response (DDR) pathway alterations are closely associated with antitumor immunity, shaping tumor immunogenicity and the immune microenvironment. Thi...